the first tests on patients of a new form of cancer treatment developed by a british company have shown promising results data published yesterday show british biotechnology's drug batimastat performed well enough with 15 patients in the trial for investigators to give additional doses to some patients professor john smyth of the imperial cancer research fund's medical oncology unit at edinburgh's western general hospital said he was very encouraged by the results of the trial which suggested the drug may be effective in the treatment of ovarian cancer it had not shown significant side effects batimastat works by acting against enzymes that destroy tissue surrounding cancer cells if the drug does well in the next two years of clinical trials it could be used in the treatment of a variety of cancers including breast lung colorectal and prostate even on patients close to death mr james noble finance director of british biotechnology said 650,000 people died of such late-stage cancers each year in europe and the us the second phase of clinical trials starts next month and the third phase which is needed for applications for approval by the world's health regulatory bodies should begin later this year cancer drugs often receive priority treatment from regulatory bodies because so many patients do not respond well enough to existing treatments batimastat works by acting against enzymes that destroy tissue surrounding cancer cells by breaking down the tissues the cancer can grow and spread british biotechnology shares rose 5 p to 450 p yesterday